L
11.67
-0.39 (-3.23%)
| Previous Close | 12.06 |
| Open | 11.90 |
| Volume | 523,463 |
| Avg. Volume (3M) | 1,112,277 |
| Market Cap | 365,153,920 |
| Price / Sales | 19.39 |
| Price / Book | 1.96 |
| 52 Weeks Range | |
| Earnings Date | 18 Mar 2026 |
| Diluted EPS (TTM) | 0.660 |
| Total Debt/Equity (MRQ) | 0.62% |
| Current Ratio (MRQ) | 23.09 |
| Operating Cash Flow (TTM) | -51.50 M |
| Levered Free Cash Flow (TTM) | -40.56 M |
| Return on Assets (TTM) | -17.75% |
| Return on Equity (TTM) | -24.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | LENZ Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.1
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 2.76% |
| % Held by Institutions | 92.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Versant Venture Management, Llc | 31 Dec 2025 | 2,656,888 |
| 72 Investment Holdings, Llc | 31 Dec 2025 | 1,017,751 |
| Intrinsic Edge Capital Management Llc | 31 Dec 2025 | 569,705 |
| C Worldwide Group Holding A/S | 31 Dec 2025 | 500,000 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Jan 2026 | Announcement | LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign |
| 14 Jan 2026 | Announcement | LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign |
| 07 Jan 2026 | Announcement | LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates |
| 05 Jan 2026 | Announcement | LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |